Drug Injury Watch: Pradaxa Safety Debate Continues During November 2012 With Many Different Conclusions And Positions

While Doctors And Hospitals Handle Patients Having Serious Bleeding Events From Pradaxa, The Drug Company Along With The FDA Still Say All Is Fine, Here

(Posted by Tom Lamb at <u>www.DrugInjuryWatch.com</u> on November 9, 2012)

SUMMARY: There was a flurry of activity in early November 2012 on the issue of whether Pradaxa (dabigatran) is an unsafe drug or a great improvement over Coumadin (warfarin).

In this article we present the developments in chronological order and you can read from the original source for any of the six items that may be of particular interest to you.

Of course, we will continue to monitor the safety profile of this controversial, still relatively new blood thinner Pradaxa and report significant developments here at Drug Injury Watch.

[Read this article in full at original source]

Earlier Pradaxa articles by Tom Lamb on the Drug Injury Watch blog:

Fall 2012: Two Recent Medical Reports Regarding Safety Of Pradaxa, Boehringer Ingelheim's Anticoagulation Drug

Increasing Number Of Pradaxa Lawsuits Against Boehringer Are Consolidated In Federal Court MDL

Pradaxa Side Effects Update Mid-2012: Deaths, Hemorrhages, Acute Renal Failure, and Stroke Events Submitted To FDA MedWatch

Safety Developments Regarding Pradaxa: Boehringer Starts Drug Registry; EMA Wants Label Change; Study Compares Pradaxa Use To Coumadin As Regards Side Effects

Pradaxa Noted For Possible Heart Attack Risk In Addition To Serious Gastrointestinal Bleeding And Other Hemorrhages

Attorney <u>Tom Lamb</u> represents people in personal injury and wrongful death cases involving unsafe prescription drugs or medication errors. The above article was posted originally on his blog, **Drug Injury Watch** – with live links and readers' Comments. <u>http://www.DrugInjuryWatch.com</u>